Essential Pharma provides access to clinically-differentiated rare disease and niche specialty medicines

• Established in 1999 as Chemidex Pharma and expanded via multiple product acquisitions within the UK; Gyrus acquired a majority stake in the business in 2019 and accelerated international growth to become a Global Specialty Pharma business leading up to the 2024 recapitalisation
• Focuses on reliable, high-quality treatments that are often difficult to manufacture, at risk of discontinuation, or require further development
• Broad portfolio with >35 brand families in >70 geographies across established medicines and novel therapeutics
• Asset light business model with ~90 FTEs and relationships with 25 CMO sites

Ensuring a continuous global supply of essential medicines for patients suffering from chronic diseases and threats of medicine discontinuation

• Diverse portfolio of differentiated, low-volume niche branded medicines poised for future growth
• Proven M&A engine to drive future growth
• R&D development program and Rare Disease strategy being executed by an industry-leading management team with a best-in-class track-record